Literature DB >> 11038211

(99m)Tc-sestamibi scintigraphy and cell cycle in parathyroid glands of secondary hyperparathyroidism.

J V Torregrosa1, L Fernández-Cruz, A Canalejo, S Vidal, E Astudillo, Y Almaden, F Pons, M Rodriguez.   

Abstract

Double-phase parathyroid MIBI ((99m)Tc-sestamibi) was performed in 27 patients with secondary hyperparathyroidism (SPT). Focal areas of increased uptake were scored for intensity on a three-point scale. All patients underwent subtotal parathyroidectomy (SPTx), and a total of 78 glands were removed at operation. Blood was obtained from the jugular vein before and after SPTx to measure the parathyroid hormone (PTH) levels. The volume and weight of the glands were calculated. The tissue was divided, with one aliquot being used for cell cycle analysis. The nuclei were acquired by flow cytometry and analyzed using CELLEIT software. Cell viability was assessed by flow cytometry and analyzed with LYSIS II software. Positive MIBI uptake was observed in 88.8% of patients. Focal MIBI uptake of one, two, or three glands was observed in 6, 11, and 8 patients, respectively. All patients experienced an 86% decrease in PTH blood level after SPTx compared to that before excision. A correlation was found between the volume of glands and the blood levels of intact PTH (iPTH) (r = 0.5, p < 0.05). A positive correlation was observed between MIBI uptake and the iPTH levels before SPTx (p < 0.01) and between the uptake of MIBI in the parathyroid glands and the cell cycle phases; low-grade uptake correlated with the G(0) phase and higher uptake with G(2)+S phase (r = 7, p < 0.01). No correlation was observed between MIBI uptake and the weight of the glands. MIBI scintigraphy accurately reflects the functional status of the hyperplastic parathyroid glands: Higher uptake grades correlated with the active growth phase. MIBI uptake does not reveal parathyroid enlargement; rather, it identifies the presence of hyperfunctioning autonomous glands. SPTx and total parathyroidectomy with autografting (TPTx+A) are the most widely accepted surgical approaches for patients with SPT. Reoperation for recurrence is necessary in 6% to 15% of cases. MIBI is now considered to be the radionuclide of reference for parathyroid gland scanning, although it is widely accepted that it produces poor results when trying to detect hyperplastic glands.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11038211     DOI: 10.1007/s002680010229

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  16 in total

1.  Evaluation of conventional imaging techniques on preoperative localization in primary hyperparathyroidism.

Authors:  Mesut Ozkaya; Umut Elboga; Ertan Sahin; Ebuzer Kalender; Hakan Korkmaz; Hasan Deniz Demir; Y Zeki Celen; Suna Erkılıç; Avni Gökalp; Göktürk Maralcan
Journal:  Bosn J Basic Med Sci       Date:  2015-02-01       Impact factor: 3.363

2.  Three-dimensional metabolic and radiologic gathered evaluation using VR-RENDER fusion: a novel tool to enhance accuracy in the localization of parathyroid adenomas.

Authors:  Jacopo D'Agostino; Michele Diana; Michel Vix; Stephane Nicolau; Luc Soler; Khalil Bourhala; Stephanie Hassler; Hurng-Sheng Wu; Jacques Marescaux
Journal:  World J Surg       Date:  2013-07       Impact factor: 3.352

Review 3.  Imaging techniques in parathyroid surgery for primary hyperparathyroidism.

Authors:  Arash Mohebati; Ashok R Shaha
Journal:  Am J Otolaryngol       Date:  2011-12-07       Impact factor: 1.808

4.  Role of pre-operative imaging using 99mTc-MIBI and neck ultrasound in patients with secondary hyperparathyroidism who are candidates for subtotal parathyroidectomy.

Authors:  David Fuster; Juan Ybarra; Jaime Ortin; José-Vicente Torregrosa; Rosa Gilabert; Xavier Setoain; Pilar Paredes; Joan Duch; Francesca Pons
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-11       Impact factor: 9.236

5.  Failed Switching off in the MIBI-Parathyroid Scintigraphy in a Dialyzed Patient with Secondary Hyperparathyroidism Responsive to Cinacalcet Therapy.

Authors:  Piergiorgio Bolasco; Alessandra Serra; Maurizio Loi; Andrea Galfré; Mario Piga
Journal:  Int J Endocrinol       Date:  2010-06-27       Impact factor: 3.257

6.  Parathyroid scintigraphy findings in chronic kidney disease patients with recurrent hyperparathyroidism.

Authors:  Elif Hindié; Paolo Zanotti-Fregonara; Pierre-Alexandre Just; Emile Sarfati; Didier Mellière; Marie-Elisabeth Toubert; Jean-Luc Moretti; Christian Jeanguillaume; Isabelle Keller; Pablo Ureña-Torres
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-28       Impact factor: 9.236

7.  Value of 123I-subtraction and single-photon emission computed tomography in addition to planar 99mTc-MIBI scintigraphy before parathyroid surgery.

Authors:  Francisca H Jorna; Pieter L Jager; Tjin H Que; Clara Lemstra; John T M Plukker
Journal:  Surg Today       Date:  2007-11-26       Impact factor: 2.549

Review 8.  Clinical value of parathyroid scintigraphy with technetium-99m methoxyisobutylisonitrile: discrepancies in clinical data and a systematic metaanalysis of the literature.

Authors:  Martin Gotthardt; Bodo Lohmann; Thomas M Behr; Artur Bauhofer; Christiane Franzius; Meike L Schipper; Maria Wagner; Helmut Höffken; Helmut Sitter; Matthias Rothmund; Klaus Joseph; Christoph Nies
Journal:  World J Surg       Date:  2003-11-26       Impact factor: 3.352

9.  Cox-2 expression in the oxyphilic cells of the normal, hyperplastic, and adenomatous parathyroid gland.

Authors:  C David Bell; Sergio Vidal; Kalman Kovacs; Jennifer Anderson; Fabio Rotondo
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

10.  Usefulness of radio-guided surgery using technetium-99m methoxyisobutylisonitrile for primary and secondary hyperparathyroidism.

Authors:  Hiroshi Takeyama; Hisashi Shioya; Yutaka Mori; Shigeyuki Ogi; Hiroyasu Yamamoto; Naohiko Kato; Satoki Kinoshita; Kazuhiko Yoshida; Ken Uchida; Yoji Yamazaki
Journal:  World J Surg       Date:  2004-06       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.